AstraZeneca asthma treatment wins regulatory nod in China
Pharmaceutical giant AstraZeneca said its dual combination asthma treatment had been approved in China.
The company's anti-inflammatory reliever, Symbicort Turbuhaler, was approved in China as...
Tue, 26/01/2021 - 07:47